1 / 42

Outlines Definitions Anti epileptic Drugs Epilepsy Surgery Vagal Nerve Stimulation Ketogenic Diet

ADVANCES IN THE MANAGEMENT OF PEDIATRIC EPILEPSY Hadassa Goldberg-Stern MD Director, Epilepsy Service Schneider Children ’ s Medical Center of Israel, Petah Tikva, Israel. Outlines Definitions Anti epileptic Drugs Epilepsy Surgery Vagal Nerve Stimulation Ketogenic Diet.

loc
Download Presentation

Outlines Definitions Anti epileptic Drugs Epilepsy Surgery Vagal Nerve Stimulation Ketogenic Diet

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADVANCES IN THE MANAGEMENT OF PEDIATRIC EPILEPSYHadassa Goldberg-Stern MDDirector, Epilepsy ServiceSchneider Children’s Medical Center of Israel, Petah Tikva, Israel

  2. Outlines • Definitions • Anti epileptic Drugs • Epilepsy Surgery • Vagal Nerve Stimulation • Ketogenic Diet

  3. DEFINITIONS • Epilepsy -a disorder of the brain characterized by a predisposition to generate epileptic seizures. (At least 2 episodes) • Epileptic Seizures – an abnormal excessive synchronous neural activity in the brain • Epileptic syndrome – based on seizure type, EEG findings, prognosis. (JME, BECTS)

  4. EPILEPSY IN CHILDREN – INCIDENCE AND PREVALENCE • 0.5% of the world population • 300,000 people have an initial seizure each year • 181,000 new cases of epilepsy each year • 120,000 are under the age of 18 years • Incidence highest under age 2 years and over 65 years

  5. WHEN TO START ANTIEPILEPTIC THERAPY? • Recurrence risk following first unprovoked seizure ranges from 27% to 76% (33%) (only 3% of recurrence occurred after 5 years). • However, epilepsy secondary to some conditions, (cortical dysplasia) have a high seizure recurrence risk.

  6. SEIZURE CLASSIFICATION Seizure types • Partial (focal, localization-related) • Generalized Seizure etiology : • idiopathic • symptomatic

  7. ANTIEPILEPTIC DRUGS • Narrow spectrum=effective for one type of seizure only (Ethosuximide) • Broad spectrum= effective for several types of seizures (Depalept, Topiramate)

  8. EPILEPSY – ALGORITHM FOR THERAPY • Antiepileptic drugs Old:Carbamazepine (Tegretol) Valproic Acid (Depalept) Phenobarbitone (Luminal) Epanutin (Dantoin) Sulthiame (Ospolot) New: Lamotrigine (Lamictal) Oxcarbamazepine (Trileptin) Topiramate (Topamax) Gabapentin (Neurontin) Levetiracetam (Keppra) Zonisamide (Zonogram)

  9. EFFICACY OF ANTIEPILEPTIC DRUGS FOR COMMON SEIZURE TYPES DRUG PARTIAL TONIC-CLONIC ABSENCE MYOCLONICATONIC/TONIC Phenobarbital + + 0 ?+ ? Phenytoin + + - - 0 Carbamazepine + + - - 0 Sodium valproate + + + + + Ethosuximide 0 0 + 0 0 Benzodiazepines + + ? + + Gabapentin + + - - 0 Lamotrigine + + + + + Oxcarbazepine + + 0 0 0 Topiramate + + ? + + Tiagabine + + - - 0 Zonisamide + + ?+ + ?+ Levetiracetam + + + + ? Felbamate + + ?+ ?+ + Vigabatrin + + - - ? _______________________________________________________________________________ + = efficacy; ?+ = probable efficacy; 0 =ineffective; - + worsens seizures; ? = unknown

  10. GENERAL ASPECTS OF PROGNOSIS FOUR GROUPS • Benign epilepsies– (20-30%) in which remission occurs after a few years and treatment can often be avoided (e.g. BECTS, Benign Occipital) • Pharmacosensitive– seizure control is easy and spontaneous remission occurs after a few years (e.g. childhood absence) • Pharmacodependent– drug treatment will control seizures but no spontaneous remission occurs (e.g. JME) 4. Pharmacoresistant (refractory) – poor prognosis

  11. ANTI EPILEPTIC DRUGS - THERAPY • Among 470 epileptic patients about 47% responded to their first AED • 13% responded to a second AED • 4% responded to a third monotherapy • Only 35 were controlled with 2 AED’s • About 30% are “pharmacoresistant” = refractory epilepsy Brodie, Neurology 2002

  12. Pharmacoresistant Epilepsy Previously Untreated Epilepsy Patients (n=470) Seizure-free with 1st drug Seizure-free with 2nd drug Seizure-free with 3rd ormultiple drugs Pharmacoresistant epilepsy 36% 47% 4% 13% Kwan P, Brodie MJ. N Engl J Med. 2000;342:314-319.

  13. EPILEPSY MANAGEMENT • 60% of newly diagnosed epilepsy patients will becontrolled on monotherapy, usually with the first or second AED chosen • 30-40% will be “refractory” • Localization-related epilepsies are less likely to be controlled than idiopathic generalized syndromes • Patients with difficult-to-control epilepsy commonly have underlying cerebral pathology and highernumbers (>20) of seizures prior to treatment

  14. STAGED APPROACH TO EPILEPSY MANAGEMENT • Tolerability and long-term safety are the most important factors in choosing the first drug • If the first AED is poorly tolerated at low dosage an alternative should be chosen • If the first AED does not completely abolish seizures – combination therapy may be tried • Work-up for epilepsy surgery should be considered after failure of two well-tolerated AED’s • If needed, subsequent combinations of two or at most three AED’s may be effective

  15. Epilepsy Surgery • ~10% of epilepsy patients become medically intractable to consider surgical therapy • Types of surgical treatment: - lesionectomy - lobectomy (Mesial Temporal Sclerosis) - corticectomy, hemispherectomy - corpus callosotomy - multiple subpial transection

  16. Contraindications to Epilepsy Surgery • Underlying degenerative or metabolic disorders • Benign epilepsy syndromes (BRE, BOE) • Idiopathic generalized epilepsy (genetic) • Multifocal EEG • Interictal psychosis relative Medication noncompliance

  17. Surgically Remediable Syndromes Chronic epilepsy associated with: • Sturge - Weber Syndrome • Tuberous Sclerosis • Focal cortical dysplasia • Hemimegalencephaly • Rasmussen’s syndrome • Low-grade cortical tumors • Hippocampal sclerosis

  18. Mesial Temporal Lobe Epilepsy (MTLE) • 70-80% of patients with MTLE will become seizure free following anterior temporal lobectomy • Early insult (prolonged febrile convulsions) • Latent period habitual seizures

  19. MTLE (cont) • History:complex febrile seizures • Clinically:Onset: First decade, complex partial seizures with an aura of epigastric rise, alimentary automatisms, amnesia for the event. • EEG: Unilateral or bilateral anterior temporal spikes

  20. Vagal Nerve Stimulation (VNS) – Historical Review • Articles from 1930’s present evidence of a vagal effect on the EEG in animals • VNS was first tried in man in November l988 by Dr. Kiffin Penry

  21. Vagus N. Stimulation in Refractory Epilepsy • Stimulation of left vagus nerve with the neuro- cybernetic prosthesis (cyberonics) • It involves surgical implantation of the generator and subcutaneous lead and connection of the lead to the cervical vagus nerve • Device stimulation begun –2 weeks after implantation • The patient is given a magnet that turns off stimulation when continually held over the generator and activates stimulation when held over the generator (may abort seizures if applied at seizure onset)

  22. Vagus Nerve: Cranial Nerve X Left cervical vagus nerve • 80% afferent fibers, mostly myelinated • 20% efferent fibers, mostly unmyelinated parasympathetic fibers to viscera, with myelinated fibers to vocal muscles Henry TR. Neurology. 2002;59(suppl 4):S3-S14.

  23. VNS Therapy

  24. Vagus N. Stimulation – Clinical Use • Refractory epilepsy to 3 AED’s used as monotherapy and 1 combination • Partial or symptomatic generalized seizures (e.g. LGS) • Unsuitability of patient for resective epilepsy surgery or when previous surgery was not successful

  25. VAGUS N. stimulation (VNS) possible mechanisms • Blocking ion currents across neuronal membranes (Na, K, Ca) • GABA – increasing brain inhibition • Attenuation of glutaminergic neurotransmission • Modifying monoaminergic regulation of seizure control However, the mechanism by which VNS modulates seizure control has not been fully elucidated

  26. VNS - Efficacy • Reduces seizure frequency by 50% in 40% of patients • 20% achieved 75% or greater reduction in seizure frequency after 1 year • Attenuates seizure severity • Positive changes in alertnessand mood • Abort seizure

  27. E05, 3 months; n=941 Registry, 3 months; n=22292 Registry, 12 months, n=22292 Improvement in Seizure Control Over Time Patient Outcome Registry and Clinical Trial Data 60 Median Seizure Reduction 56% 50 43% 40 30 Reduction (%) 23% 20 10 0 12 months E05 3 months 1Handforth A, et al. Neurology. 1998;51:48-55. 2Data on file. Cyberonics, Inc. Houston, TX; April 25, 2003.

  28. VNS Therapy Long-term Seizure Control in Pediatric Patients (EO1-EO5) 50 44% 37% 40 31% 30 Median Decrease in Seizure Frequency (%) 23% 20 10 0 3 months 6 months 12 months 18 months Last Visit Carried Forward (n=60) Murphy JV.J Pediatr.1999,134 (5):563-566.

  29. VNS Therapy Quality of Life in Patients <18 Years Patient Outcome Registry (Constant Cohort) Patients/Parents Report Better or Much Better Alertness Post-ictal Clusters Verbal Skills Mood Achievements 3 Months (n=743) 12 Months (n=743) Memory 0 10 20 30 40 50 60 70 80 Patients (%) Fewer than 8% of patients/parents reported worse or much worse outcome by any single measure Data on file. Cyberonics, Inc. Houston, TX; April 25, 2003.

  30. VNS – side effects • Voice changes may occur Dyspnea on exertion with stimulation • Surgical complications: infection (1.5%) vocal cord paresis (1%) unilateral facial weakness (1%) • No effect on heart rate

  31. Ketogenic Diet • An alternative for intractable epilepsy not amenable to surgery since 1920’s • Fasting for seizure control has been suggested since biblical times

  32. Ketogenic Diet – Possible Mechanisms • Acidosis • Water balance and dehydration • Direct action of acetoacetate or hydroxybutyrate • Changing energy sources of the brain from glucose to ketones

  33. Ketogenic diet-clinical use • Absence • Symptomatic myoclonic • Lennox-Gaustaut Sy At Johns Hopkins: “The Ketogenic diet is considered for all children who have intractable seizures of any type and from any cause who have not responded to a variety of regimens”.

  34. Ketogenic Diet • Classic: Ratio of Ketogenic to antiketogenic is 4 : 1 fat (protein + carbohydrates) • The diet allows 1 gr of protein/kg body weight daily • Restriction of fluids • Vitamins supplement

  35. Ketogenic Diet - efficacy • 1/3 – complete seizure control • 1/3 – greater than 50% seizure improvement • 1/3 – no improvement • 2/3 – one drug reduced • 10% - all drugs discontinued

  36. Ketogenic Diet –Side effects • Renal stones • Hyperuricemia • Acidosis • Hypocalcemia • Eating problems • Secondary carnitine deficiency

  37. Epilepsy Treatments Age ChildrenAdults Primarily children Children Adults Children Adults Indication Specific AEDs for specific seizure types All seizure types Pharmacoresistant or localisation-related epilepsy Pharmacoresistant epilepsy, localisation-related seizures Efficacy 64% sz freedom1 54% pts >50% sz reduction at 3 months2 70% in select patients sz freedom3 43% of pts >50% sz reduction at 3 years4 Side Effects Vary by AED, typically CNS- and endocrine-related Lipid disorders, ketoacidosis Cognitive effects, surgery-related risks Voice alteration, cough, pharyngitis, dyspnea Treatment AEDs Ketogenic Diet Epilepsy Surgery VNS Therapy 1Brodie MJ, Kwan P. Neurology. 2002;58(suppl 5):S2-S8. 2Vining EP, et al. Arch Neurol. 1998;55:1433-1437. 3Van Ness PC. Arch Neurol. 2002;59:732-735. 4Morris GL III, Mueller WM. Neurology. 1999;53:1731-1735.

  38. Agatha Christie Thomas Edison Joan of Arc Alexander the Great Leonardo Da Vinci Feodor Dostoevski Jullius Caesar Charles Dickens Napoleon Bonaparte

  39. Thank you

More Related